Table 4.

Pharmacokinetics of the new derivatives.

S/N	MW	log P	HBA	HBD	TPSA	AMR	nRB	nA	nAc	ABS %	LNV	RNV
17a	497	0.648	7	0	160.7	134.93	9	34	0	53.8	0	1
17b	586	2.423	7	0	160.7	168.29	11	41	0	53.8	1	2
17c	625	2.03	8	0	160.7	180.15	11	44	0	53.8	1	2
17d	552	2.609	7	0	160.7	152.41	11	38	0	53.8	1	2
17e	552	2.398	7	0	160.7	151.03	11	38	0	53.8	1	2
17f	538	1.829	7	0	160.7	147.96	10	37	0	53.8	1	2
17g	449	–0.62	7	0	143.63	112.6	6	30	0	59.45	0	0
17h	432	0.406	6	0	143.63	109.55	6	29	0	59.45	0	0
17i	417	–0.24	7	0	100.49	113.66	5	28	0	74.33	0	0
17j	401	0.792	6	0	100.49	110.61	5	27	0	74.33	0	0
17k	403	–0.63	7	0	100.49	109.38	5	27	0	74.33	0	0
17l	387	0.40	6	0	100.49	106.33	5	26	0	74.33	0	0

MW: molecular weight; HBA: hydrogen bond acceptor; HBD: hydrogen bond donor; TPSA: total polar surface area; nRB: number of rotatable bond; nAc: number of acid; AMR: molar refractivity; nA: number of atoms; LNV: Lipinski’s number of violations; RNV: Reckitt’s number of violation.